EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis Treatment

Churu Mao, Shuai Zhan, Zhangyun Fang, Jiebin Fang iD, Yun Huang, Wanjing Ding, Zhongjun Ma iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c03411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Churu Mao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China. Hauptthemen laut MEDLINE: rho-Associated Kinases, Dermatitis, Atopic, Drug Design, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Science and Technology Department of Zhejiang Province, Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City, the Seed Fund Cultivation Project of Ocean College, Zhejiang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) remains a significant clinical challenge due to the limited efficacy and safety concerns associated with current therapies. To address this unmet need, we utilized structure-guided analysis and identified a previously unrecognized hydrophobic surface (S1) unique to ROCK2. Exploiting this structural feature through virtual screening led to the discovery of compound 10d, a potent ROCK2 inhibitor with markedly improved selectivity compared to the reference compound KD025. In a mouse model of MC903-induced AD, 10d effectively suppressed inflammation and achieved therapeutic efficacy superior to the model group, while maintaining a favorable safety profile. Mechanistically, we demonstrated that 10d attenuates AD pathology by downregulating S100A9, highlighting the ROCK2-S100A9 axis as a novel pathway in AD pathogenesis. Collectively, these findings establish 10d as a highly active and selective inhibitor, marking the first exploration of ROCK2-targeted therapy for AD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesDermatitis, AtopicDrug DesignProtein Kinase InhibitorsAnimalsMiceHumansStructure-Activity Relationship

Substanzen

rho-Associated KinasesProtein Kinase InhibitorsROCK2 protein, humanRock2 protein, mouse

Autor:innen und Institutionen

  • Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
  • Hainan Institute of Zhejiang University, Sanya 572025, China.

ORCID-Profile: Jiebin Fang, Zhongjun Ma

Förderung

  • Science and Technology Department of Zhejiang Province
  • Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City
  • the Seed Fund Cultivation Project of Ocean College, Zhejiang University

Zitieren

APA

Mao, C., Zhan, S., Fang, Z., Fang, J., Huang, Y., Ding, W., & Ma, Z. (2026). Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03411

Vancouver

Mao C, Zhan S, Fang Z, Fang J, Huang Y, Ding W, et al. Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis Treatment. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03411

BibTeX
@article{Mao2026,
  author = {Mao, Churu and Zhan, Shuai and Fang, Zhangyun and Fang, Jiebin and Huang, Yun and Ding, Wanjing and Ma, Zhongjun},
  title = {Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c03411}
}
Kostenlos starten →